This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Histone deacetylase 6 (HDAC6); histone deacetylase 8 (HDAC8)	<p><i>In vitro</i> studies suggest dual inhibition of HDAC6 and HDAC8 could help treat cancer. Inhibition of HDAC6 or HDAC8 has been shown to promote cancer cell death. In a panel of HDACs, BRD73954 selectively inhibited HDAC6 and HDAC8 with nanomolar IC₅₀ values. Next steps include testing BRD73954 in models for neuroblastoma and using the compound to identify substrates for HDAC6 and HDAC8.</p> <p>Acetylon Pharmaceuticals Inc.'s rocilinostat, an oral selective HDAC6 inhibitor, is in Phase I/II testing to treat multiple myeloma. At least three other companies have compounds that inhibit HDAC6 or HDAC8 in preclinical development to treat various cancers or inflammation.</p> <p>SciBX 6(23); doi:10.1038/scibx.2013.572 Published online June 13, 2013</p>	Patent application filed; available for licensing	<p>Olson, D.E. <i>et al. J. Med. Chem.</i>; published online May 14, 2013; doi:10.1021/jm400390r</p> <p>Contact: Edward Holson, Broad Institute of MIT and Harvard, Cambridge, Mass. e-mail: edholson@broadinstitute.org</p>